Get the StoQuant digest — free
Free StoQuant digest by email. No account needed.
See today's research picks.
MMED vs NAMS — Stock Comparison
Compare MMED and NAMS side-by-side on StoQuant: MMED Q-Score 79 vs NAMS 24; analyst signal 81 vs 79. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.
Side-by-side snapshot
- MMED — MiniMed Group, Inc. Common Stock · Health Care · market cap $5.16B · Q-Score verdict Strong Buy (79.0, grade A) · analyst signal 81/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: analyst consensus 93/100, technicals 80/100 · weakest signals: competitive moat 30/100. Full MMED research.
- NAMS — NewAmsterdam Pharma Company N.V. · Health Care · market cap $2.30B · Q-Score verdict Strong Sell (24.0, grade F) · analyst signal 79/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 97/100, analyst consensus 88/100 · weakest signals: technicals 7/100. Full NAMS research.
What you can compare
- Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
- Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
- Insider activity: Cluster scores and recent Form 4 buying.
- Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
- Strategic edges: Competitive moat and durable advantage analysis.
- Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
- Macro context: Market regime and sector rotation alignment.
Deep dive: MMED research · NAMS research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →
Register founding interest — Pro $29/mo or Power $79/mo
Paid plans aren’t for sale yet. Leave your email to lock founding pricing (Pro $29, Power $79); we’ll reach out personally.